💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Windlas Biotech Limited is a domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). Its portfolio of CDMO solutions includes product development, licensing, and commercial manufacturing of complex drugs and dosage forms. Its product…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, steadily growing business, fully valued.
Windlas Biotech is scored on the pharma / healthcare framework. It keeps a slim 7.2% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.58× reported profit. Free cash flow is worth about 0.6% of its market value.
Over the last 3 years revenue compounded at 21%/yr and profit at 16%/yr. Book value has grown 13%/yr. Return on equity is a healthy 12.2%. In the latest quarter profit grew 7% versus the prior quarter.
At 31× earnings, the stock sits at the 71st percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~11%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 23.42 | — | — |
| P/B | 2.68 | 4.1 | better |
| EV/EBITDA | 12.98 | 19.33 | better |
| ROE | 12.23 | — | — |
| ROCE | 15.82 | 14.41 | better |
| ROA | 10.73 | — | — |
| Quick Ratio | 1.76 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 21% CAGR over 3 years — high-growth territory.
Net profit has risen every year — the hallmark of a compounder. Revenue is outpacing profit (21% vs 16%) — costs are rising faster than the top line.
Operating margins have been stable around 9% — no major structural shift.
ROE at 11% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. 17% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.6× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 9% above earlier ones.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 63.3% — majority control intact. Promoters added 1.4pp over 4 quarters — creeping acquisition signals conviction. MF stake down 4.0pp — domestic funds are booking profits or rebalancing out.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.